Nowadays, the sunscreen creams are composed of mostly synthetic chemicals and other organic compounds which were found to enter into the blood stream on topical application raising concerns in the scientific community. The scientific community has now shifted their attention to herbal formulations due to toxicity of these synthetic molecules. Aloe vera is a xerophitic plant having excellent anti-oxidant properties. The permeation effect and drug stability of the drug candidate can be significantly enhanced by formulating it into solid lipid nanoparticles (SLN). The main objectives of the study were to formulate and evaluate Aloe vera-loaded SLN sunscreen cream and to determine its photoprotective potential. The Aloe vera-loaded SLNs were formulated by microemulsification technique. The developed SLNs were studied for its entrapment efficiency, poly dispersity index (PDI), zeta potential, particle size, and other characterization techniques. Finally, the optimized SLNs were incorporated into the sunscreen cream and evaluated for its spreadability, viscosity, extrudability, drug content, in vitro drug release, ex vivo permeation, determination of sun protection factor (SPF), skin irritation test, and accelerated stability studies. The in vitro SPF was found out to be 16.9 ± 2.44 and the in vivo SPF observed to be approximately 14.81 ± 3.81, respectively. Stability studies were performed under accelerated conditions and no appreciable changes in the parameters were noticed. The solid lipid nanoparticles of Aloe vera were incorporated into a cream and the SPF of the resultant sunscreen cream was found to be on par with the sunscreens that were currently available in the market.

Exploring the photo protective potential of solid lipid nanoparticle-based sunscreen cream containing Aloe vera.

Syphilis among sexually transmitted infections clinic attendees in a tertiary care institution: a retrospective data analysis.

We report a case of 30-year-old female who presented initially with hair loss, photosensitive malar rash, morning stiffness and synovitis. She was diagnosed with Rhupus syndrome based on clinical and laboratory findings. Few months after starting hydroxychloroquine, esomeprazole and azathioprine, and failing methotrexate (because of erosive pill-induced esophagitis), she presented with generalized maculopapular dusky reddish rash in her body, back and extremities. Her anti-double stranded-DNA, anti-nuclear antibody, anti-Ro/SSA and anti-La/SSB were positive. Anti-cyclic citrullinated peptide antibody was moderately positive. She had low complements: C3 and C4. Herpes simplex IgM and mycoplasma tested negative. Skin biopsy from right arm showed evidence of erythema multiform. She met the criteria for the diagnosis of Rowell syndrome. We managed her with hydroxychloroquine, prednisolone, mycophenolate mofetil and topical agents and discontinued esomeprazole. We also review the management of Rowell syndrome in the literature.

/pdf/a-case-of-rhupus-with-rowell-syndrome-23ri4dlqbd.pdf

A Case of Rhupus with Rowell Syndrome.

Rowell syndrome (RS) is a rare disease characterized by the association of systemic lupus erythematosus (SLE) or cutaneous lupus with lesions similar to erythema multiforme and the presence of autoantibodies including ANA, SSA, SSB, or rheumatoid factor. Due to the low incidence of this disease, the epidemiology of RS is not clear. So far there are 95 cases reported in the literature; of these, only seven cases are pediatric patients. Macrophage activation syndrome (MAS) is an increasingly recognized complication of SLE, although its true prevalence in childhood is still unknown. We describe a unique pediatric patient with RS who developed MAS.

Rowell syndrome complicated with macrophage activation syndrome in a child.

Rowell's syndrome (RS) is recognized since 1963 as a presentation of lupus erythematosus (LE) with erythema multiforme-like lesions and characteristic immunological changes. Antiphospholipid syndrome (APS) encompasses antibodies to phospholipids/phospholipid-binding cofactor proteins and/or circulating lupus anticoagulant with clinical manifestations of thrombosis such as recurrent spontaneous abortions, etc. A 32-year-old female with primary infertility since marriage (7 years) and sequential appearance, for the past 6 months, of various lupus-specific cutaneous lesions, “targetoid” lesions on palms, musculoskeletal, ocular and auditory (sensorineural hearing loss [SNHL]) complaints with positive serological profile for SMD-1, SS-A/Ro, SS-B/La, U1-snRNP, Ku, antiphospholipid and anticardiolipin antibodies, and histopathologically confirmed LE is presented as a case of concurrent overlap syndrome, RS and APS, primary infertility, and SNHL. A brief review of RS including analysis of data of cases reported from India hereto vis-a-vis that of cases worldwide up to 2012 has also been done.

Overlap syndrome with rowell's syndrome, antiphospholipid syndrome, primary sterility, and sensorineural hearing loss: A case report, brief review, and analysis of cases of rowell's syndrome reported from India and Abroad

Rowell's syndrome is now identified as a subtype of subacute lupus erythematosus (LE) with erythema multiforme-like skin lesions, positive serum rheumatoid factor, anti-Ro La positivity and speckled pattern of antinuclear antibodies. Here we describe a case of Rowell's syndrome in an 18-year-old female who was found to be ds-DNA negative, who later progressed to develop stage V lupus nephritis (LN) over a course of 4 months. Although extremely rare, most cases of LN are drug induced. Of only seven cases of non-drug induced LN with negative dsDNA, none had cutaneous involvement. Ours was a unique case of progression of Rowells syndrome to ds-DNA negative LN.

Rowell's Syndrome to ds-DNA Negative Lupus Nephritis: A Yet Unreported Progression.

How to cite this article: Sookaromdee P, Wiwanitkit V. Anti‐human immunodeficiency virus serology status and pre‐ and post‐test counseling: A note. Indian J Sex Transm Dis 2016;37:89‐90. This is an open access article distributed under the terms of the Creative Commons Attribution‐NonCommercial‐ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non‐commercially, as long as the author is credited and the new creations are licensed under the identical terms. the cases with seronegativity. Of interest, those with seronegativity and within window period usually get no posttest counseling. It is needed to find a method to increase the coverage of posttest counseling.[2]

Saurabh Jindal

Papers

Rowell's Syndrome to ds-DNA Negative Lupus Nephritis: A Yet Unreported Progression.

Syphilis incognito: Resurgence of the covert devil

Anatomy and Physiology of Skin